The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Wee1 kinase as a target for cancer therapy
Open accessAbstract
Wee1, a protein kinase, regulates the G 2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. MK-1775, a selective and potent small-molecule inhibitor of wee1, is under clinical development as a potentiator of DNA damage caused by cytotoxic chemotherapies. We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clinical development to date of this novel class of anticancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064
Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog
Russell, P., & Nurse, P. (1987) · Cell · doi:10.1016/0092-8674(87)90458-2 · Cited by 1,017
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190030497 · Cited by 829
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., & Iliakis, G. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl840 · Cited by 820
DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1
Ira, G., Pellicioli, A., Balijja, A., Wang, X., Fiorani, S., Carotenuto, W., Liberi, G., Bressan, D., Wan, L., Hollingsworth, N. M., et al. (2004) · Nature · doi:10.1038/nature02964 · Cited by 722
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666
Cited by
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Cervical cancer therapies: Current challenges and future perspectives
Burmeister, C. A., Khan, S. F., Schäfer, G., Mbatani, N., Adams, T., Moodley, J., & Prince, S. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200238 · Cited by 474
Targeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
Ubiquitin signaling in cell cycle control and tumorigenesis
Dang, F., Nie, L., & Wei, W. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00648-0 · Cited by 348
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Leijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 264
Stewart, E., McEvoy, J., Wang, H., Chen, X., Honnell, V., Ocarz, M., Gordon, B., Dapper, J., Blankenship, K., Yang, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.012 · Cited by 153
Integrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
Targeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102
Ha, D.-H., Min, A., Kim, S., Jang, H., Kim, S. H., Kim, H.-J., Ryu, H. S., Ku, J.-L., Lee, K.-H., & Im, S.-A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66018-5 · Cited by 78
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00147 · Cited by 77
Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
Aublette, M. C., Harrison, T. A., Thorpe, E. J., & Gadd, M. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128636 · Cited by 35
Metadata
- Authors
- Do, K., Doroshow, J. H., & Kummar, S.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2013-10
- Volume
- 12
- Issue
- 19
- Pages
- 3348-3353
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W1973388314
- Cited by
- 273
- References
- 40
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.